NCT00411762View on ClinicalTrials.gov

A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Pancreatic Cancer
Interventions
DRUG

Capecitabine

DRUG

PHY906

Trial Locations (1)

06519

Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven

Sponsors

Collaborators (1)

PhytoCeutica
All Listed Sponsors
collaborator

PhytoCeutica

INDUSTRY

collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Roche Pharma AG

INDUSTRY

lead

Yale University

OTHER